Bárcena Juan, Zamora-Ceballos María, Blanco Esther
Centro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Madrid, Spain.
Subcell Biochem. 2024;105:785-821. doi: 10.1007/978-3-031-65187-8_21.
Virus-like particles (VLPs) are formed by viral proteins that, when overexpressed, spontaneously self-assemble into particles that structurally are similar to infectious virus or subviral particles (e.g. the viral capsid). VLPs are appealing as vaccine candidates because their inherent properties (i.e. virus-sized, multimeric antigens, highly organised and repetitive structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. VLP-based vaccines have already been licensed for human and veterinary use, and many more vaccine candidates are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines. This chapter provides an overview on the design and use of VLPs for the development of new-generation vaccines.
病毒样颗粒(VLPs)由病毒蛋白形成,当这些病毒蛋白过度表达时,会自发地自我组装成在结构上与感染性病毒或亚病毒颗粒(如病毒衣壳)相似的颗粒。VLPs作为疫苗候选物很有吸引力,因为它们的固有特性(即病毒大小、多聚体抗原、高度有序且重复的结构、无感染性)适合诱导安全有效的体液免疫和细胞免疫反应。基于VLP的疫苗已获许可用于人类和兽医领域,目前还有更多的候选疫苗正处于评估后期。此外,将VLPs开发为外源抗原展示平台进一步拓宽了它们作为预防性和治疗性疫苗的潜在应用范围。本章概述了VLPs在新一代疫苗开发中的设计与应用。
Subcell Biochem. 2024
Subcell Biochem. 2013
Viruses. 2023-5-2
Arch Virol. 2023-6-13
Cell Mol Immunol. 2022-9
Expert Rev Vaccines. 2022-4
NPJ Vaccines. 2021-5-13
Virology. 2021-4
Nat Rev Immunol. 2021-2
Lancet. 2020-11-7